Gilead Sciences (GILD) Stock Climbs On Great Earnings

Gilead Sciences, Inc. (NASDAQ: GILD) As expected, Gilead Sciences reported it’s quarterly earnings report yesterday after the bell. Also meeting my expectations, the company did far better in the first quarter than most analysts expected it to do. So, today we’ll take a look at the earnings report for the quarter, chat about how the … Read more

Gilead Sciences (GILD) | Earnings Should Be A Hit!

Gilead Sciences, Inc. (NASDAQ: GILD) Gilead Sciences is expected to release its earnings report today after the bell. So naturally, curiosity strikes and I’ve decided to take a look at what we can expect to see. Here are a few things to keep in mind before the earnings release… GILD HCV Earnings Shouldn’t Be A … Read more

Gilead Sciences (GILD) Isn’t Scared Of AbbVie (ABBV) | Neither Are Investors

Gilead Sciences, Inc. (NASDAQ: GILD) For quite some time now, Gilead Sciences has dominated the hepatitis C treatment arena; and for good reason. In the past, treatment of hepatitis C lasted 48 weeks and included a wide variety of vaccines. Sadly enough, there was no where near a 100% success rate in treatment. However, Sovaldi … Read more

Is Merck & Co. A Real Threat To Gilead Sciences & AbbVie Inc?

Gilead Sciences, Inc. (NASDAQ: GILD) | AbbVie Inc (NYSE: ABBV) Gilead Sciences and AbbVie Inc play a major role in the Hepatitis C Virus treatment market. The combination of Sovaldi, Harvoni (GILD) and Viekira (ABBV) is not only incredibly effective in treating the virus, the combination is the market leader around the world. Considering the … Read more